Dr. Cohen talks about the potential for bringing CAR T-cell therapy to heavily-pretreated myeloma patients, as well as the potential toxicities.
Adam D. Cohen, MD: Expanding CAR T Cells to Treat Myeloma
Recent Articles
Telehealth Services Pose Privacy Concerns
Retailers – from Amazon to Walmart – are expanding their health-care services to include virtual visits with health-care professionals. While convenient for patients, the...
Cutting Patient Protections to Cut Costs?
The Trump administration proposed that reducing guaranteed coverage of certain drugs for Medicare beneficiaries would lower costs. The coverage requirement has been in place...
Scientist Investigated for Illegal Genetic Editing
Michael Deem, PhD, professor of biochemical and genetic engineering at Rice University in Houston, is being investigated by his employer for his connection to...
Rivaroxaban Reduces Thrombotic Risk in Patients Undergoing Cancer Treatment
Primary prevention with the direct oral anticoagulant (DOAC) rivaroxaban reduced venous thromboembolism (VTE) and VTE-related mortality in patients with cancer, according to results from...
New Tool Provides Simple Approach to Pausing Direct Oral Anticoagulants for Surgery
Researchers have developed a “simple, standardized, easy-to-use” strategy to guide decisions about interrupting direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) scheduled...
Current Issue
December 2018, Volume 4, Issue 14
This issue features a look at the consequences of medical errors, an update on the Cancer Moonshot Initiative, a preview of 2018 ASH Annual Meeting, and more.
